Glucose-6-phosphate dehydrogenase deficiency

Glucose-6-phosphate dehydrogenase (G6PD) is expressed in all tissues, where it catalyses the first step in the pentose phosphate pathway. G6PD deficiency is prevalent throughout tropical and subtropical regions of the world because of the protection it affords during malaria infection. Although most...

Full description

Saved in:
Bibliographic Details
Published inBailliere's best practice & research. Clinical haematology Vol. 13; no. 1; pp. 21 - 38
Main Authors Mehta, Atul, Mason, Philip J., Vulliamy, Tom J.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.03.2000
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Glucose-6-phosphate dehydrogenase (G6PD) is expressed in all tissues, where it catalyses the first step in the pentose phosphate pathway. G6PD deficiency is prevalent throughout tropical and subtropical regions of the world because of the protection it affords during malaria infection. Although most affected individuals are asymptomatic, there is a risk of neonatal jaundice and acute haemolytic anaemia, triggered by infection and the ingestion of certain drugs and broad beans (favism). A rare but more severe form of G6PD deficiency is found throughout the world and is associated with chronic non-spherocytic haemolytic anaemia. Many deficient variants of G6PD have been described. DNA sequence analysis has shown that the vast majority of these are caused by single amino acid substitutions. The three-dimensional structure of G6PD shows a classical dinucleotide binding domain and a novel β+α domain involved in dimerization.
ISSN:1521-6926
1532-1924
DOI:10.1053/beha.1999.0055